In the last year, AcuraStem entered into an agreement with Brian Trust Bio to profile FDA approved drugs on a patient’s living motor neurons. Similar in our approaches in how we identify ALS drug targets, it was a natural collaboration to support their precision medicine program. For the AcuraStem team, the project has proven to be vital in advancing our own knowledge of patient-based research in ALS. We look forward to the year ahead, as AcuraStem’s first therapeutic drug candidate for ALS draws nearer to clinical trials and we continue to build on our work together with Brian Trust Bio.